QIAGEN is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding QIAGEN N.V., the company operates more than 35 offices in over 25 countries. The main operative headquarters are located in Hilden, Germany.
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential
QIAGEN news
27.04.2022
QIAGEN's GAAP net income for 3 months of 2022 was $155.312 million, up 20.2% from $129.223 million in the previous year. Revenue increased by 10.8% to $628.391 million compared to $567.206 million a year earlier.
Source: s28.q4cdn.com
09.02.2022
QIAGEN's GAAP net income for 2021 was $512.599 million, up 42.7% from $359.188 million in the previous year. Revenue increased 20.4% to $2.252 billion compared to $1.87 billion a year earlier.
Source: s28.q4cdn.com
04.11.2021
QIAGEN's GAAP net income for 9M 2021 was $383.413 million, up 2.6 times from $146.503 million in the previous year. Revenues increased by 28.5% to $1.669 billion from $1.299 billion a year earlier.
Source: s27.q4cdn.com
30.07.2021
QIAGEN's GAAP net income for the six months of 2021 was $250.274 million, up 93.1% from $129.593 million in the previous year. Revenues increased 39.3% to $1.135 billion from $0.815 billion a year earlier.
Source: s27.q4cdn.com
General information
| Company name | QIAGEN |
|---|---|
| Tags | #medtech, #dax index |
| Sector | Health Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Equipment |
| Business address | Hulsterweg 82 Venlo, 5912 PL Netherlands |
| Website | corporate.qiagen.com |
| Information disclosure | www.sec.gov |
English (US) 